Nautilus Biotechnology is trading at $2.62, down 19.29%, with no company-specific catalyst identified.
- Q3 2026 results are scheduled before market open on October 27; the report is upcoming, not a newly announced cause of the October 26 decline.
- Major indices were modestly higher, and trading volume information was unavailable in the provided price context.